What does this research mean for the field?

The grade of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), as determined by the ASTCT consensus grading system, should be used to guide clinical management. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The review aims to establish a comprehensive grading system for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) to improve patient management.

May 17, 2026Evidence to Action Official Journal of MDCalc0 citations

Review of Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)

AWAustin WesevichUniversity of Chicago

Key Points

The review aims to establish a comprehensive grading system for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) to improve patient management.
Development of a consensus grading system by the American Society for Transplantation and Cellular Therapy (ASTCT).
Integration of prior grading systems including CTCAE and CARTOX for better assessment of neurotoxicity.
Guideline focus on management strategies based on the grade of ICANS.
The consensus grading system helps clinicians accurately assess the severity of ICANS.
Utilizing the grading system could lead to enhanced management strategies for patients undergoing immune effector cell therapies.

Abstract

The American Society for Transplantation and Cellular Therapy (ASTCT) developed this consensus grading system based on prior Common Terminology Criteria for Adverse Events (CTCAE) and Immune Effector Cells Therapy Toxicity Assessment and Management (CARTOX) grading systems. Grade of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) should guide management.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper